Ripretinib as fourth-line therapy showed to improve progression-free survival in patients with advanced gastrointestinal stromal tumours (GIST) in the phase III INVICTUS trial presented today. According to Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland, results are surprisingly good in this difficult to treat population of patients.
INVICTUS trial: positive results for patients with GIST
